Literature DB >> 10535887

Resolution of chronic delta hepatitis after 12 years of interferon alfa therapy.

D T Lau1, D E Kleiner, Y Park, A M Di Bisceglie, J H Hoofnagle.   

Abstract

Chronic delta hepatitis is an uncommon but severe form of chronic viral hepatitis for which there is currently no satisfactory therapy. A patient with chronic delta hepatitis was treated with interferon alfa, 5 million units daily for 12 years. Serial serum samples were tested for routine liver tests and selected samples for quantitative levels of hepatitis B surface antigen (HBsAg) and hepatitis delta virus RNA. Liver biopsies were performed before, during, and after an initial 1-year course of therapy and again after 3 and 10 years of continuous therapy. With initiation of interferon therapy, serum aminotransferase levels decreased to normal range, became abnormal again when the dose was reduced, and increased to pretreatment levels when therapy was stopped. With reinstitution and prolonged therapy, aminotransferase levels became persistently normal; after several years, both hepatitis delta virus RNA and serum HBsAg became undetectable. Liver biopsy, which initially revealed cirrhosis, showed gradual improvement in inflammatory and fibrosis scores and, after 10 years, no abnormalities or fibrosis. Therapy was stopped, and the patient remained free of evidence of infection. In conclusion, long-term therapy with interferon alfa in high doses led to resolution of chronic delta hepatitis, disappearance of hepatitis delta and B virus markers, and improvement in fibrosis.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10535887     DOI: 10.1016/s0016-5085(99)70409-9

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  24 in total

Review 1.  Interferon alpha for chronic hepatitis D.

Authors:  Zaigham Abbas; Muhammad Arsalan Khan; Mohammad Salih; Wasim Jafri
Journal:  Cochrane Database Syst Rev       Date:  2011-12-07

Review 2.  Hepatitis delta virus: A fascinating and neglected pathogen.

Authors:  Celso Cunha; João Paulo Tavanez; Severin Gudima
Journal:  World J Virol       Date:  2015-11-12

3.  Alpha interferon and ribavirin combination therapy of chronic hepatitis D.

Authors:  Sabahattin Kaymakoglu; Cetin Karaca; Kadir Demir; Sule Poturoglu; Ahmet Danalioglu; Selim Badur; Murvet Bozaci; Fatih Besisik; Yilmaz Cakaloglu; Atilla Okten
Journal:  Antimicrob Agents Chemother       Date:  2005-03       Impact factor: 5.191

4.  Cost-Effectiveness of Peg-Interferon, Interferon and Oral Nucleoside Analogues in the Treatment of Chronic Hepatitis B and D Infections in China.

Authors:  Ashish Goyal; John M Murray
Journal:  Clin Drug Investig       Date:  2016-08       Impact factor: 2.859

5.  Molecular and clinical aspects of hepatitis D virus infections.

Authors:  Elham Shirvani Dastgerdi; Ulf Herbers; Frank Tacke
Journal:  World J Virol       Date:  2012-06-12

6.  Long-term therapy of chronic delta hepatitis with peginterferon alfa.

Authors:  T Heller; Y Rotman; C Koh; S Clark; V Haynes-Williams; R Chang; R McBurney; P Schmid; J Albrecht; D E Kleiner; M G Ghany; T J Liang; J H Hoofnagle
Journal:  Aliment Pharmacol Ther       Date:  2014-05-11       Impact factor: 8.171

7.  Treatment options for hepatitis delta virus infection.

Authors:  Benjamin Heidrich; Michael P Manns; Heiner Wedemeyer
Journal:  Curr Infect Dis Rep       Date:  2013-02       Impact factor: 3.725

Review 8.  Epidemiology, pathogenesis and management of hepatitis D: update and challenges ahead.

Authors:  Heiner Wedemeyer; Michael P Manns
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2010-01       Impact factor: 46.802

Review 9.  Therapy of Delta Hepatitis.

Authors:  Cihan Yurdaydin; Ramazan Idilman
Journal:  Cold Spring Harb Perspect Med       Date:  2015-08-07       Impact factor: 6.915

10.  Regression of fibrosis in paediatric autoimmune hepatitis: morphometric assessment of fibrosis versus semiquantiatative methods.

Authors:  Ahmed F Abdalla; Khaled R Zalata; Abeer F Ismail; Gamal Shiha; Mohamed Attiya; Ahmed Abo-Alyazeed
Journal:  Fibrogenesis Tissue Repair       Date:  2009-04-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.